Roth Capital Re-Initiates GW Pharma (GWPH) at Buy

Roth Capital re-initiates coverage on GW Pharma (NASDAQ: GWPH) with a Buy rating and a price target of $130.00.

The analyst sees blockbuster potential. "We estimate that Epidiolex would be priced at $36,000 per year in 2017 (market entry) in the U.S. and at $24,000 in Europe. By assuming a gradual ramp from 1% market share in the launch year growing to 33% by 2022 (by 2024 in Europe), peak sales potential approaches $3B by our calculation. By 2024, we estimate that 73,000 patients (~10% of all children with epilepsy) would be treated with Epidiolex, which assumes a substantial off label use, justified by the experience in the expanded access program."

For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.

Shares of GW Pharma closed at $84.90 yesterday.

You May Also Be Interested In

• Barrington Research Starts CBIZ, Inc. (CBZ) at Outperform
• TD Cowen Downgrades Flowserve Corp. (FLS) to Hold
• FedEx (FDX) PT Lowered to $350 at UBS on Lowered EPS Estimates